智通财经APP讯，沛嘉医疗-B(09996)发布公告，本公司已入组ReachTactile™机器人辅助经导管主动脉 瓣置换(TAVR)系统(该系统)首例患者。于2025 年9月17日，北部战区总医院的韩雅玲院士团队成功完成 首例患者治疗，利用ReachTactile™机器人辅助TAVR系统为一名重度主动脉瓣狭窄患者植入 TaurusElite®经导管主动脉瓣膜。该系统的注册临床试验是一项前瞻性、多中心、随机对照、非劣效性 研究，旨在评估ReachTactile™机器人辅助TAVR系统及其一次性手术包在TAVR手术中的安全性及有效 性。是次试验结果将纳入本公司未来向国家药品监督管理局(药监局)提交的注册申请。 ReachTactile™是本公司内部研发的机器人辅助TAVR系统，为TAVR治疗提供创新、高性价比的解决方 案。可模块化移动的设计适配于传统的血管介入导管室，允许一名心脏病专家以亚毫米级的精度操作多 台器械。该系统搭载的力传感机制可提供即时触觉反馈，有助于在复杂的血管条件下的器械导航通行。 基于主从控制布局能够有效降低术者辐射暴露等职业健康风险。同时，基于以太网的远程控制功能可实 现跨地域手术操作及操作 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，本 公 司 已 入 組ReachTactile™機 器 人 輔 助 經 導 管 主 動 脈 瓣 置 換（「TAVR」）系 統（「該系統」）首 例 患 者。於2025 年9月17日，北部戰區總醫院的韓雅玲院士團隊成功完成首例患者治療， 利 用ReachTactile™機器人輔助TAVR系統為一名重度主動脈瓣狹窄患者植入 TaurusElite®經導管主動脈瓣膜。該系統的註冊臨床試驗是一項前瞻性、多中心、 隨機對照、非劣效性研究，旨在評估ReachTactile™機器人輔助TAVR系統及其 一次性手術包在TAVR手術中的安全性及有效性。是次試驗結果將納入本公司 未來向國家藥品監督管理局（「藥監局」）提交的註冊申請。 – 1 – 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 ...

Peijia Medical Limited 沛嘉醫療有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 9996) September 25, 2025 Dear non-registered shareholder(s), Reminder Letter regarding the Arrangement of Electronic Dissemination of Corporate Communications Should you have any queries relating to this letter, please contact the Company at +86 (512) 8187 7166 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding public holidays. Yours fa ...

Solicitation of electronic contact details Peijia Medical Limited 沛嘉醫療有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 9996) Dear registered shareholder(s), September 25, 2025 Reminder Letter regarding the Arrangement of Electronic Dissemination of Corporate Communications With reference to the notification letter of Peijia Medical Limited (the "Company") dated 12 November 2024 titled "Arrangement of Electronic Dissemination of Corporate Communications", th ...

(於開曼群島註冊成立之有限公司) 股份代號: 9996 中期報告 Interim Report Interim Report 2025 中期報 告 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 業務摘要 | | 9 | 管理層討論及分析 | | | 補充資料 | | 63 | 簡明綜合財務報表審閱報告 | | | 簡明綜合損益及其他全面收益表 | | | 簡明綜合財務狀況表 | | | 簡明綜合權益變動表 | | | 簡明綜合現金流量表 | | | 簡明綜合財務報表附註 | | 100 | 釋義 | | 33 64 65 67 68 70 | | 公司資料 董事會 執行董事 張一博士 （董事長兼首席執行官） 張葉萍太太 葉紅女士 非執行董事 關繼峰先生 陳飛先生 楊俊先生 獨立非執行董事 Stephen Newman OESTERLE博士 Robert Ralph PARKS先生 葉偉明先生 衛華誠先生 審核委員會 葉偉明先生 （主席） 關繼峰先生 Robert Ralph PARKS先生 衛華誠先生 薪酬委員會 Robert Ralph PARKS先生 （ ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

转自：新华财经 编者按：创新联合体是推动创新链深度融合、突破产业关键核心技术、提升企业及产业核心竞争力的重要机制，既深度契合现阶段技术创新"跨产业、多领 域交叉"的特征，更能显著提升重大研究成果产出效率与创新技术商业化转化效能。近年来，苏州工业园区以关键核心技术攻关重大任务为牵引，引导建设 了一批"利益融合、要素融通、能力融汇"的创新联合体，为突破重点产业发展瓶颈提供有力支撑。 在苏州工业园区（以下简称"园区"），一种生态融合型创新联合体正持续激发"化合反应"，推动科技创新与产业创新深度融合，加速高端医疗器械技术从实 验室走向生产线。作为苏州生物医药领域首个生态融合型创新联合体，苏州市介入医疗技术创新联合体由沛嘉医疗科技（苏州）有限公司（以下简称"沛嘉 医疗"）牵头组建，构建形成"龙头企业引领+上下游创新型企业参与+科研机构联合攻关+孵化器培育+投资基金支持"的运行模式，着力打造集技术攻关、平 台建设、企业孵化、成果转化、产业培育、人才引进与临床医学服务为一体的产业创新生态，实现空间上集聚、创新上集成、产业上协同，孵化出众多创新 产品、高性能材料与优质项目，助推区域高端医疗器械产业高质量发展。 空间上集聚：整 ...

Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

Major Events - Alibaba-W (09988) announced the pricing of $3.2 billion zero-coupon convertible preferred notes, with an initial conversion price of $193.15 per American depositary share [1] - Peijia Medical-B (09996) reported the first human clinical trial implantation of the Sutra Hemi-valve transcatheter mitral valve repair system [1] - Corning Jereh Pharmaceutical-B (09966) received acceptance from the National Medical Products Administration for the new drug application of KN026 (Anni monoclonal antibody injection) [1] - Nissin Foods (01475) invested 30.68 million yuan to acquire two plots of land in Zhuhai for the construction of new production facilities [1] - Nocoda Technology (00519) signed a cooperation agreement for low-altitude economic intelligent drones [1] Financial Data - Country Garden Holdings (00754) reported total contract sales of approximately 9.902 billion yuan for the first eight months, a year-on-year decrease of 15.56% [1] - China General Nuclear Power Corporation (01811) completed a power generation of 1,543.7 GWh in August, a year-on-year decrease of 5.7% [1] - Xinte Energy (00956) achieved a cumulative power generation of 9.8787 million MWh in the first eight months, a year-on-year increase of 10.55% [1] - Oceanwide Holdings (03377) reported a cumulative contracted sales amount of approximately 16.44 billion yuan for the first eight months, a year-on-year decrease of 25.88% [1]

Core Viewpoint - Sutra Medical, Inc. has successfully completed the first-in-man clinical trial of its Sutra Hemi-valve transcatheter mitral valve repair system, indicating a significant advancement in treating severe functional mitral regurgitation in high-risk patients [1] Company Summary - Sutra Medical, Inc. is a company in which the group holds a strategic investment [1] - The first application of the Sutra Hemi-valve system was performed on an 83-year-old high-risk patient with severe functional mitral regurgitation [1] - The procedure took place at Waikato Hospital in New Zealand, showcasing the company's international reach and clinical capabilities [1] Industry Summary - The successful implantation of the Sutra Hemi-valve system represents a potential breakthrough in the treatment options available for patients who are not suitable for traditional therapies [1] - The positive outcome of the procedure, with the patient recovering well and being discharged on the third day, highlights the effectiveness and safety of the new medical technology [1]